Biocon Biologics debuts in Asia IP Elite list

BENGALURU: Biocon Biologics, a subsidiary of Biocon, has been recognised as one of the ASIA IP ELITE in 2019 list for its intellectual property management “consistent value creation”.
Biocon, the Bengaluru-headquartered bio-pharma firm and the parent company for Biocon Biologics, has has been recognised as the ASIA IP ELITE for the fourth year in a row. Biocon’s subsidiary received this award at the recently concluded IP Business Congress Asia in Tokyo, Japan, said the company in a press release.

Biocon Biologics has a product pipeline of 28 molecules, including 11 partnered with Mylan, several with Sandoz, and many being developed independently. The company's therapeutic basket includes molecules from diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases.

In 2016, Biocon became the first and only Indian pharma company to be featured on the prestigious ASIA IP ELITE list. “This recognition is an endorsement of Biocon Group's strategy of value creation through innovation and IP to serve patient needs across the world.

Biocon Biologics has a strong portfolio of IP assets with granted patents and trademarks. Our IP team has demonstrated a sustained commitment to building best-in-class in-house IP function focussed on continuous excellence in IP value creation,” Christiane Hamacher, chief executive officer, Biocon Biologics, was quoted saying.